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Purpose: To synthesize a series of novel 3-ethyl-2-substituted amino-quinazolin-4(3H)-ones and 
evaluate them for their analgesic and anti-inflammatory activities.  
Methods: The compounds, 3-ethyl-2-substituted amino-quinazolin-4(3H)-ones, were synthesized by 
reacting the amino group of 3-ethyl-2-hydrazino quinazolin-4(3H)-one with a variety of aldehydes and 
ketones. The synthesized compounds were characterized by Fourier transform infrared (FTIR), proton-
nuclear magnetic resonance spectroscopy (1H-NMR) and mass spectrometry. The purity of the 
compounds was determined by elemental analysis. Test for analgesic activity was performed by tail-flick 
technique using Wistar albino mice while anti-inflammatory activity was evaluated by carrageenan-
induced paw oedema test in rats. Diclofenac sodium was used as positive control for both analgesic and 
anti-inflammatory activities.  
Results: The compound, 3-ethyl-2-(cyclohexylidene-hydrazino)-3H-quinazolin-4-one (AS1), emerged 
as the active analgesic (activity, 63.89 %) and anti-inflammatory (activity, 60.00 %) compound of the 
series, and compared well with the reference standard, diclofenac sodium, which exbited analgesic and 
anti-inflammatory activities of 62.04 and 65.11 %, respectively 
Conclusion: The compound (AS1) can serve as a lead molecule for further development to a clinically 
useful novel class of analgesic and anti-inflammatory agents. 
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Nonsteroidal anti-inflammatory drugs (NSAIDs) 
are commonly prescribed for the treatment of 
acute and chronic inflammation, pain and fever. 
Most NSAIDs act via inhibition of cyclooxy-
genase, thus preventing prostaglandin 
biosynthesis. However, this mechanism of action 
is also responsible for their main undesirable 
effects, gastrointestinal (GI) ulceration and, less 
frequently, nephrotoxicity. Increase in 
hospitalization and deaths due to GI-related 
disorders parallels increased use of NSAIDs. 
Therefore, the discovery of new safer anti-
inflammatory drugs represents a challenging goal 
for such a research area [1-4].  
 
In the course of our going medicinal chemistry 
research program it was found that quinazolines 
and condensed quinazolines exhibit potent 
central nervous system (CNS) activities including 
analgesic, anti-inflammatory [5] and 
anticonvulsant behavior [6]. Quinazolin-4(3H)-
ones with 2,3-substitution are reported to 
possess significant analgesic, anti-inflammatory 
[7,8] and anticonvulsant activities [9]. Earlier, we 
have documented some lead 2-phenyl-3-
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substituted quinazolines (Figure 1, I) [10], 2-
methyl-3-substituted quinazolines (Figure 1, II) 
[11], 2-methylthio-3-substituted quinazaolines 
(Figure 1, III) [12], and 2,3-disubstituted 
quinazolines [13] that exhibited good analgesic 
and anti-inflammatory properties.  
 
The present work is an extension of our ongoing 
efforts towards the development and 
identification of new molecules for analgesic and 
anti-inflammatory activities. The objective of the 
present study was to synthesize a series of 3-
ethyl-2-substitutedamino-quinazolin-4(3H)-ones 













Melting points (mp) were taken in open 
capillaries on a Thomas Hoover melting point 
apparatus and are uncorrected. IR spectra of the 
synthesized compounds were recorded by FT-IR 
(Shimadzu, Japan) using KBr pellet ( max in 
cm-1). The NMR spectra of the synthesized 
compounds were recorded in deuterated 
chloroform (CDCl3) (unless specified) with 
tetramethyl silane (TMS) as internal reference 
(chemical shift in , ppm) using Varian 300 MHz 
and Bruker 500 MHz (Washington, USA) 
spectrometers. The mass spectra of the 
compounds were obtained on Jeol GC mate 
instrument (Masspec, Japan). Elemental 
analyses were performed in Perkin-Elmer 2400 
CHN elemental analyzer (Waltham, USA). The 
progress of the reaction was monitored on 
readymade silica gel plates (Merck) using 
chloroform : methanol (9:1) as a solvent system. 
Iodine was used as a developing agent. 
 
3-Ethyl-2-thioxo-2,3-dihydro-1H-quinazolin-4-
one (4)   
 A solution of ethylamine (1.31 g, 0.02 mol) in 
dimethyl sulfoxide (10 mL) was stirred vigorously. 
To this was added carbon disulphide (1.6 mL) 
and aqueous sodium hydroxide (1.2 mL of 20 M 
solution) dropwise during 30 min with stirring. 
Dimethyl sulphate (2.5 g, 0.02 mol) was then 
added gradually, keeping the reaction mixture in 
freezing mixture with stirring which was 
continued for further 2 h. The reaction mixture 
was then poured into ice-water and the solid 
obtained was filtered, washed with water, dried 
and recrystallized from 95 % ethanol. 
 
Methyl anthranilate (3) (1.5 g; 0.01 mol) and the 
above prepared N-(ethyl) methyl dithiocarbamic 
acid (0.01 mol) were dissolved in ethanol (20 
mL). To this anhydrous potassium carbonate 
(100 mg) was added and refluxed for 23 h.  The 
reaction mixture was cooled in ice and the solid 
separated was filtered and purified by dissolving 
in 10 % alcoholic sodium hydroxide solution (2N) 
and re-precipitating by treatment with 20 % dilute 
hydrocholoric acid. The solid obtained was 
filtered, washed with water, and dried. It was 






quinazolin-4-one (4)  (2.05 g, 0.01 mol), was 
dissolved in 40 mL of 2 % ethanol-sodium 
hydroxide solution (2N). To this, dimethyl sulfate 
(5.0 mL, 0.01 mol) was added dropwise for 15 
min with stirring. The stirring was continued for 1 
h, the reaction mixture was then poured into ice 
water.  The solid obtained was filtered, washed 
with water, dried and recrystallized from 95 % 
ethanol. 
 
3-Ethyl-2-hydrazino--3H-quinazolin-4-one (6)  
 
The compound, 3-ethyl-2-methylsulfanyl-3H-
quinazolin-4-one (5) (2.19 g, 0.01 mol), was 
dissolved in ethanol (95 %, 25 mL). To this, 
hydrazine hydrate (99 %) (0.5 mL, 0.1 mol) and 
anhydrous potassium carbonate  (100 mg) was 
added and refluxed for 28 h at inert atmosphere. 
The reaction mixture was cooled and poured into 
ice-water. The solid obtained was filtered, 
washed with water, dried and recrystallized from 
chloroform : toluene (25:75) mixture.  
 
3-Ethyl-2-(cyclohexylidene-hydrazino)-3H-
quinazolin-4-one (AS1)  
 
A mixture of 3-ethyl-2-hydrazino-3H-quinazolin-4-
one (6) (800 mg, 0.004 mol) and cyclohexanone 
(0.004 mol) in glacial acetic acid (0.25 mL) was 
refluxed for 30 h.  The reaction mixture was 
poured into ice water and filter.  The solid filter 
cake was recrystallized from ethanol.  
 
3-Ethyl-2-(N-(4-nitro-benzylidene-hydrazino))-
3H-quinazolin-4-one (AS2)  
 
A mixture of 3-ethyl-2-hydrazino-3H-quinazolin-4-
one (6) (800 mg, 0.004 mol) and 4-nitro 





























Sheorey et al 




































































Scheme 1: Synthesis of 3-ethyl-2-substitutedamino-3H-quinazolin-4-ones 
 
acetic acid (0.25 mL) was refluxed for 33 h. The 
reaction mixture was poured into ice water and 




hydrazino))-3H-quinazolin-4-one (AS3)  
A mixture of 3-ethyl-2-hydrazino-3H-quinazolin-4-
one (6) (800 mg, 0.004 mol) and 4-methoxy 
benzalhedyde (545 mg, 0.004 mol) in glacial 
acetic acid (0.25 mL) was refluxed for 32 h. The 
reaction mixture was poured into ice water and 
filter.  The solid filter cake was recrystallized from 
ethanol.   
 
3-Ethyl-2-(N-(4-methyl-benzylidene-
hydrazino)-3H-quinazolin-4-one (AS4)  
A mixture of 3-ethyl-2-hydrazino-3H-quinazolin-4-
one (6) (800 mg, 0.004 mol) and 4-methyl 
benzalhedyde (480 mg, 0.004 mol) in glacial 
acetic acid (0.25 mL) was refluxed for 30 h.  The 
reaction mixture was poured into ice water and 




3H-quinazolin-4-one (AS5)  
A mixture of 3-ethyl-2-hydrazino-3H-quinazolin-4-
one (6)  (800 mg, 0.004 mol) and diphenyl 
ketone (730 mg, 0.004 mol) in glacial acetic acid 
(0.25 mL)  was refluxed for 35 h.  The reaction 
mixture was poured into ice water and filter.  The 
solid filter cake was recrystallized from ethanol.  
 
Animal studies  
 
The synthesized compounds were evaluated for 
analgesic and anti-inflammatory activities. The 
test compounds and the standard drugs were 
administered in the form of a suspension (1 % 
aO / tO  
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carboxy methyl cellulose as a vehicle) by oral 
route. Each group consisted of six animals. The 
animals were maintained in colony cages at 25 ± 
2 C, relative humidity of 45 – 55 %, and 12 h/12 
h light/dark cycle; they were fed standard animal 
feed. All the animals were acclimatized for a 
week before use [14]. The experimental protocol 
was duly approved by the institutional animal 
ethical committee (IAEC, F. No.25/559/2010-
AWD) constituted by the Committee for the 
Purpose of Control and Supervision of 
Experimental Animals (CPCSEA), Ministry of 
Environment and Forest, New Delhi, India (IAEC, 
F. No.25/559/2010-AWD). 
 
Analgesic activity  
 
Test for analgesic activity was performed by tail-
flick technique [15,16] using Wistar albino mice 
(25 - 35 g) of either sex selected by random 
sampling. Diclofenac sodium, at dose levels of 5, 
10 and 20 mg/kg, was administered orally by 
gastric lavage as reference drug for comparison. 
The test compounds at three dose levels (5, 10, 
20 mg/kg) were administered orally. Reaction 
time was recorded at 30 min, 1, 2 and 3 h after 
treatment, and cut-off time was 10 s. Analgesic 
activity (AA, %) was calculated as in Eq 1. 
AA (%) = {(T2 – T1)/(10 – T1)}100 ……… (1) 
where T1 is the reaction time (s) before 
treatment, and T2 the reaction time (s) after 
treatment. 
 
Anti-inflammatory activity  
 
Anti-inflammatory activity was evaluated by 
carrageenan-induced paw oedema test in Wistar 
Albino rats [17]. Diclofenac sodium (5, 10 and 20 
mg/kg) was administered as a standard drug for 
comparison. The test compounds were 
administered orally at three dose levels of 5, 10 
and 20 mg/kg. Paw volume was measured using 
mercury displacement technique with the aid of a 
plethysmograph immediately before and 30 min, 
1, 2 and 3 h after carrageenan injection. 
Inhibition (I, %) of paw oedema was calculated 
as in Eq 2. 
I (%) = 100{1- (a-x)/(b-y)} ………………. (2) 
 
where x is mean paw volume of the rats before 
administration of carrageenan and test 
compounds or reference compound (test group), 
a is the mean paw volume of rats after the 
administration of carrageenan in the test group 
(drug-treated), b is the mean paw volume of rats 
after the administration of carrageenan in the 
control group, y is the mean paw volume of rats 
before administration of carrageenan in the 
control group. 
Statistical analysis  
 
Statistical analysis of the biological activities of 
the synthesized compounds in the animals was 
carried out using one-way analysis of variance 
(ANOVA). In all cases, post-hoc comparisons of 
the means of individual groups were performed 
using Tukey's test. A significance level of p < 
0.05 denote significant difference in all cases. All 
values are expressed as mean ± standard 
deviation (SD). GraphPad Prism 3.0 version. 
(GraphPad GraphPad Software, Inc.11452 El 
Camino Real, #215, San Diego, CA 92130 USA) 




The key intermediate 3-ethyl-2-thioxo-2,3-
dihydro-1H-quinazolin-4-one 4 (Scheme 1) was 
prepared  by reacting ethyl amine (1) with carbon 
disulphide and sodium hydroxide in dimethyl 
sulphoxide to give sodium dithiocarbamate, 
which was methylated with dimethyl sulfate to 
afford the dithiocarbamic acid methyl ester (2). 
Compound 2 on reflux with methyl anthranilate 
(3) in ethanol yielded the desired 3-ethyl-2-
thioxo-2,3-dihydro-1H-quinazolin-4-one (4) via 
thiourea intermediate and gave a good yield (85 
%). It was confirmed by IR spectra of compound 
4 show intense peaks at 3250 cm-1 for cyclic thio 
urea (NH), 1668 cm-1 for carbonyl (C=O) and 
1220 cm-1  for thioxo (C=S) stretching. 1H NMR 
spectra of 4 showed multiplet around δ 1.0-2.0 
and 7.10-7.50 for ethyl (5H) protons and 
aromatic (4H) protons respectively; and a singlet 
at δ 10.55 indicating the presence of NH. Data 
from elemental analysis were in conformity with 
the assigned structure. Further, the molecular ion 
recorded in the mass spectra is also in 
agreement with the molecular weight of the 
compound. 
 
The IR spectra of compound 5 showed 
disappearance of NH and C=S stretching signals 
of cyclic thiourea. It showed a peak for carbonyl 
(C=O) stretching at 1680 cm-1. The 1H NMR 
spectra of compound 5 showed singlets due to  
SCH3, at δ 2.70,  multiplet around 7.20-7.60  for 
aromatic (4H) protons, respectively. Data from 
the elemental analyses and molecular ion 
recorded in the mass spectra further confirmed 
the assigned structure. 
 
Nucleophilic displacement of methylthio group of 
5 with hydrazine hydrate was carried out using 
ethanol as solvent to afford 3-ethyl-2-hydrazino-
3H-quinazolin-4-one 6. The formation of 6 was 
confirmed by 1H NMR spectra which showed 
singlets at  4.56 and 10.31 due to NH2 and NH, 
respectively, a multiplet at δ 1-1.5 and 7.15-7.30 
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for ethyl (5H) protons and aromatic (4H) protons 
respectively. The NH and NH2 signals at 3330, 
3205 cm-1 are appeared in the IR spectra. It also 
showed a peak for carbonyl (C=O) at 1670 cm-1. 
Data from the elemental analyses are in 
conformity with the assigned structure. Further, 
the molecular ion recorded in the mass spectra is 
also in agreement with the molecular weight of 
the compound. 
 
The compounds, 3-ethyl-2-substituted amino-3H-
quinazolin-4-ones AS1 - AS5 were obtained by 
the condensation of amino group of 3-ethyl-2-
hydrazino-3H-quinazolin-4-one (6) with a variety 
of aldehydes and ketones. Formation of product 
is indicated by the disappearance of peak due to 
NH2 of the starting material in IR and 1H NMR 
spectrum of all the compounds AS1 - AS5. The 
IR 1H NMR spectra of these compounds showed 
the presence of peaks due to (N=CR1R2) 
carbonyl (C=O), NH and aryl groups. The mass 
spectra of the the compounds show molecular 
ion peaks corresponding to their molecular 
formula. In the mass spectra of compounds AS1 
- AS5, a common peak at m/z 144 corresponding 
to quinazolin-4-one moiety appeared. Elemental 
(C, H, N) analysis satisfactorily confirmed rhe 




one (4)  
 
Yield = 85 %, mp 290-291°C; IR (KBr) cm-1: 3250 
(NH), 1668 (C=O), 1220 (C=S); 1H NMR (CDCl3) 
: 0.95-1.05 (t, 3H, CH2CH3),1.39-1.50 (q, 2H, 
CH2CH3), 7.10-7.50 (m, 4H, ArH), 10.55 (br s, 
1H, NH, D2O Exchangeable); MS (m/z): 206 
(M+);  Anal. Calcd. for C10H10N2OS: C, 58.22; H, 





  Yield = 86 %, mp 173-174 °C; IR (KBr) cm-1: 
1680 (C=O), 1605 (C=N); 1H NMR (CDCl3)  : 
0.90-1.10 (t, 3H, CH2CH3), 1.35-1.52 (q, 2H, 
CH2CH3), 2.70 (s, 3H, SCH3), 7.20-7.60 (m, 4H 
ArH); MS (m/z): 220 (M+); Anal. Calcd for 
C11H12N2OS: C, 59.97; H, 5.49; N, 12.71. Found: 




Yield = 80 %, mp 193-195 °C; IR (KBr) cm-1: 
3330, 3205 (NH NH2), 1670 (C=O), 1610 (C=N); 
1H NMR (CDCl3):  0.91-1.00 (t, 3H, CH2CH3), 
1.30-1.48 (q, 2H, CH2CH3), 4.56 (br s, 2H, NH2 
D2O Exchangeable), 7.15-7.30 (m, 4H, ArH), 
10.31 (br s, 1H, NH D2O Exchangeable); MS 
(m/z): 204 (M+); Anal. Calcd for C10H12N4O: C, 
58.81; H, 5.92; N, 27.43. Found: C, 58.85; H, 





Yield = 73 %, mp 224-226 °C; IR (KBr) cm-1 : 
3250 (NH), 1690 (C=O), 1612 (C=N); 1H-NMR 
(CDCl3): δ 0.91-1.10 (t, 3H, CH2CH3), 1.29-1.86 
(m, 10H, CH2 cyclohexyl), 1.98-2.03 (q, 2H, 
CH2CH3), 7.62-7.91 (m, 4H, ArH), 8.90 (br s, 1H, 
NH, D2O Exchangeable); MS (m/z): 284 (M+); 
Anal. Calcd. for C16H20N4O: C, 67.58; H, 7.08; N, 





Yield = 71 %, mp 282-283 °C; IR (KBr) cm-1 : 
3268 (NH), 1679 (C=O), 1612 (C=N); 1H-NMR 
(CDCl3): δ 1.26-1.32 (t, 3H, CH2CH3), 1.64-1.75 
(q, 2H, CH2CH3), 6.12 (s, 1H, CH), 8.02-9.13 (m, 
8H, ArH), 9.53 (br s, 1H, NH, D2O 
Exchangeable); MS (m/z): 337 (M+); Anal. Calcd. 
for C17H15N5O3: C, 60.52; H, 4.48; N, 20.76. 
Found: C, 60.58; H, 4.53; N, 20.73. 
 
3-Ethyl-2-(N-(4-methoxy-benzylidene-
hydrazino))-3H-quinazolin-4-one (AS3)  
 
Yield = 77 %, mp 268-270 °C; IR (KBr) cm-1: 
3305 (NH), 1690 (C=O), 1610 (C=N); 1H-NMR 
(CDCl3): δ 1.04-1.18 (t, 3H, CH2CH3), 1.42-1.55 
(q, 2H, CH2CH3), 3.36 (s, 3H, OCH3), 6.08 (s, 
1H, CH), 7.22-8.31 (m, 8H, ArH), 9.03 (br s, 1H, 
NH, D2O Exchangeable); MS (m/z): 322 (M+); 
Anal. Calcd. for C18H18N4O2: C, 67.00; H, 5.63; 





Yield = 74 %, mp 286-288 °C; IR (KBr) cm-1 : 
3260 (NH), 1682 (C=O), 1605 (C=N); 1H-NMR 
(CDCl3): δ 0.82-0.96 (t, 3H, CH2CH3), 1.15-1.23 
(q, 2H, CH2CH3), 2.15 (s, 3H, CH3), 6.14 (s, 1H, 
CH), 7.05-8.01 (m, 8H, ArH), 9.36 (br s, 1H, NH, 
D2O Exchangeable); MS (m/z): 306 (M+); Anal. 
Calcd. for C18H18N4O: C, 70.50; H, 5.92; N, 





Yield = 73 %, mp 267-269 °C; IR (KBr) cm-1: 
3316 (NH), 1690 (C=O), 1608 (C=N); 1H-NMR 
(CDCl3): δ 0.93-1.06 (t, 3H, CH2CH3), 1.26-1.33 
(q, 2H, CH2CH3), 6.11 (s, 1H, CH), 7.25-7.45 (m, 
4H, ArH), 7.72-8.51 (m, 10H, ArH), 9.51 (br s, 
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1H, NH, D2O Exchangeable); MS (m/z):  368 
(M+); Anal. Calcd. for C23H20N4O: C, 75.05; H, 
5.47; N, 15.20. Found: C, 75.09; H, 5.46; N, 
15.23. 
 
The results of analgesic testing indicate that the 
test compounds exhibited moderate analgesic 
activity at 30 min of reaction time and an 
increase in activity at 1 h which reached a peak 
level at 2 h. Decline in activity was observed at 3 
h (Table 1). 
 
Anti-inflammatory activity data (Table 2) indicate 
that all the test compounds protected rats from 
carrageenan-induced inflammation moderately at 
30 min of reaction time with increased activity at 
1 h that reached a peak level at 2 h. Decline in 
activity was observed at 3 h. 
 
Table 1: Analgesic activity of the synthesized compounds (AS1 - AS5)  
 
Analgesic activity (%) Compound 
code 
Dose 
(mg/kg) 30 min 1 h 2 h 3h 
AS1 5 22.45 ± 2.04c 28.70 ± 2.81c 34.72 ± 3.82c 16.44 ± 4.21b 
 10 37.27 ± 1.65c 44.91 ± 4.06c 51.62 ± 3.86c 31.71 ± 3.33c 
 20 50.23 ± 2.69c 59.72 ± 3.16c 63.89 ± 3.34c 40.05 ± 2.46c 
AS2 5 19.68 ± 2.54c 23.61 ± 4.36 c 29.63 ± 4.14 c 13.66 ± 1.73 a 
 10 29.63 ± 2.99c 35.45 ± 4.42c 41.43 ± 3.17c 26.13 ± 3.96c 
 20 39.35 ± 2.70c 45.14 ± 1.88c 46.99 ± 2.54c 35.42 ± 0.93c 
AS3 5 20.37 ± 2.52b 26.62 ± 2.22c 32.41 ± 3.47c 13.89 ± 5.45a 
 10 34.03 ± 1.98c 40.05 ± 2.47c 43.75 ± 3.14c 27.78 ± 4.66c 
 20 42.13 ± 2.88c 51.85 ± 4.71c 56.02 ± 2.28c 37.96 ± 3.54c 
AS4 5 21.53 ± 1.88c 29.17 ± 3.72c 37.04 ± 2.99c 19.68 ± 2.54c 
 10 35.42 ± 0.93c 41.20 ± 2.50c 45.14 ± 1.88c 28.70 ± 5.93c 
 20 44.21 ± 2.96c 54.17 ± 3.00c 59.95 ± 2.46c 37.73 ± 4.07c 
AS5 5 18.52 ± 2.90c 24.54 ± 3.26c 28.47 ± 2.26c 16.44 ± 2.71c 
 10 31.48 ± 2.62c 37.04 ± 2.99c 43.29 ± 5.32c 32.87 ± 3.88c 
 20 41.20 ± 2.50c 48.84 ± 2.83c 54.63 ± 2.65c 37.04 ± 5.04c 
Control  1.852 ± 1.85 Ns 5.787 ± 2.59 Ns 7.870 ± 2.50 Ns 3.935 ± 2.49 Ns 
Diclofenac Na 5 21.76 ± 2.20c 31.48 ± 2.62c 35.42 ± 4.41c 17.59 ± 2.52b 
 10 35.18 ± 3.89c 42.82 ± 5.20c 48.61 ± 5.83c 29.17 ± 3.42c 
 20 48.15 ± 4.47c 58.33 ± 4.40c 62.04 ± 3.54c 37.96 ± 3.54c 
Data expressed as mean    SD from six different experiments, each carried out in duplicate;  ap < 0.05, bp < 0.01and cp < 
0.001 a compared with their respective positive control 
 
Table 2: Anti-inflammatory activity of the synthesized compounds (AS1 - AS5) 
 
Inhibition/Protection (%) Compound 
code 
Dose 
(mg/kg) 30 min 1 h 2 h 3h 
AS1 5 26.31 ± 9.98a 30.16 ± 4.82b 35.55 ± 3.40c 20.76 ± 2.10a 
 10 35.18 ± 10.40b 42.85 ± 8.54c 46.67 ± 1.46c 38.59 ± 3.11b 
 20 47.36 ± 9.21c 57.14 ± 4.64c 60.00 ± 3.84c 45.61 ± 3.12c 
AS2 5 12.28 ± 4.00a 20.23 ± 3.88a 25.78 ± 1.70a 16.95 ± 1.37a 
 10 28.06 ± 6.17b 28.57 ± 4.47b 32.89 ± 4.06c 21.92 ± 5.21a 
 20 31.57 ± 6.07c 38.09 ± 5.53c 41.33 ± 3.86c 30.70 ± 2.86c 
AS3 5 21.05 ± 5.08c 28.57 ± 2.68c 32.00 ± 2.17c 19.29 ± 1.28c 
 10 28.07 ± 9.28b 34.12 ± 4.94b 36.44 ± 3.38c 23.97 ± 4.25a 
 20 36.84 ± 6.65c 42.85 ± 2.53c 44.00 ± 2.17c 35.08 ± 2.18c 
AS4 5 15.79 ± 5.92a 26.19 ± 2.38c 26.50 ± 3.78c 17.54 ± 1.17b 
 10 26.31 ± 6.92b 30.95 ± 6.47c 32.66 ± 3.89c 27.19 ± 2.42b 
 20 31.57 ± 4.90c 38.09 ± 3.88c 48.00 ± 2.00c 32.46 ± 1.26c 
AS5 5 16.66 ± 6.28a 23.80 ± 4.21c 28.00 ± 1.37c 17.54 ± 1.01a 
 10 21.05 ± 8.59a 32.14 ± 5.79b 41.33 ± 4.35c 21.32 ± 2.08a 
 20 26.31 ± 7.31b 40.47 ± 4.12c 48.00 ± 1.91c 29.82 ± 3.46c 
Control  1.52 ± 1.85 Ns 5.87 ± 2.59 Ns 7.87 ± 2.50 Ns 3.93 ± 2.49 Ns 
Diclofenac Na  5 16.66 ± 4.38a 24.20 ± 5.47b 30.66 ± 4.68c 20.17 ± 1.82b 
 10 32.45 ± 9.83b 36.50 ± 4.33c 43.78 ± 3.69c 33.04 ± 2.97b 
 20 41.22 ± 8.74c 54.36 ± 6.06c 65.11 ± 4.49c 47.22 ± 8.06c 
Data expressed as mean     SD from six different experiments, each carried out in duplicate;  ap < 0.05, bp < 0.01and cp < 
0.001 a compared with their respective positive control 
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All the synthesized compounds were confirmed 
by spectral data (IR, NMR and mass spectra). 
Elemental (C, H, N) analysis satisfactorily 
confirmed elemental composition and purity of 
the synthesized compounds. 
         
Compound AS1 with 1-cyclohexylidene 
substituent showed good analgesic activity. 
Replacement of an alkyl chain at the C-2 position 
with aryl group (compound AS3, AS4, AS5) 
leads to decrease in analgesic activity. 
Placement of aryl group with electron 
withdrawing substituent (compounds AS5) leads 
to further decrease of analgesic activity. 
Compound 3-ethyl-2-(cyclohexylidene-hydrazi-
no)-3H-quinazolin-4-one (AS1) emerged as the 
most active analgesic agent and it is moderately 
more potent than the reference standard, 
diclofenac sodium. The compound, 3-ethyl-2-
(cyclohexylidene-hydrazino)-3H-quinazolin-4-one 
(AS1), emerged the most active anti-
inflammatory agent. Replacement of an alkyl 
chain at the C-2 position with aryl group 
(compound AS3, AS4, AS5) leads to decrease in 
anti-inflammatory activity. Placement of aryl 
group with electron withdrawing substituent 





The synthesized compounds exhibited promising 
analgesic and anti-inflammatory activities. 
Among them, compound 3-ethyl-2-
(cyclohexylidene-hydrazino)-3H-quinazolin-4-one 
(AS1) is the most active compound of the series 
and is as potent as the reference standard 
(diclofenac sodium). Hence, this compound is a 
potential lead molecule for a clinically useful 
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